EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Moonlighting ERAP Aminopeptidases in Cancer: Beyond Antigen Processing

Paula Gragera iD, Valentina Scaldaferri iD, Doriana Fruci iD

Cells · 2026

DOI: 10.3390/cells15171609 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Paula Gragera und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ospedale Pediatrico Bambino Gesù IRCCS, 00146 Rome, Italy. Hauptthemen laut MEDLINE: Aminopeptidases, Neoplasms. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Italian Association for Cancer Research, Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy has transformed the treatment of multiple malignancies; however, primary and acquired resistance remain major clinical challenges. Because effective immune recognition depends on the repertoire of peptides presented by major histocompatibility complex class I (MHC-I) molecules, increasing attention has focused on the antigen processing and presentation pathway as a therapeutic target to enhance tumor immunogenicity. Among its key regulators, the endoplasmic reticulum (ER) aminopeptidases ERAP1 and ERAP2 shape the MHC-I immunopeptidome by trimming peptide precursors before antigen presentation. Beyond this canonical function, accumulating evidence indicates that ERAP aminopeptidases are multifunctional proteins involved in inflammation, angiogenesis, ER stress responses, cell migration, and tumor-intrinsic signaling. These moonlighting activities suggest that ERAP enzymes influence cancer progression through both immune-dependent and immune-independent mechanisms. Recent advances in medicinal chemistry have enabled the development of selective ERAP1 inhibitors, leading to the first clinical evaluation of this therapeutic strategy and providing early clinical evidence that pharmacological modulation of antigen processing may complement existing immunotherapies. In this review, we summarize the multiple functions of ERAP aminopeptidases in cancer, discuss their role in regulating adaptive and innate immune responses, and highlight emerging therapeutic strategies and future challenges for exploiting ERAP-targeted interventions in precision immuno-oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopeptidasesNeoplasmsAntigen PresentationHumansAnimalsMinor Histocompatibility Antigens

Stichwörter der Autor:innen

ERAP1ERAP2antigen processingcancercancer immunotherapyprecision oncologytargeted therapy

Substanzen

ERAP1 protein, humanERAP2 protein, humanAminopeptidasesMinor Histocompatibility Antigens

Autor:innen und Institutionen

  • Ospedale Pediatrico Bambino Gesù IRCCS, 00146 Rome, Italy.

ORCID-Profile: Paula Gragera, Valentina Scaldaferri, Doriana Fruci

Förderung

  • European Union
  • Italian Association for Cancer Research
  • Ministry of Health
  • Associazione Italiana Ricerca
  • CAPSTONE-ETN H2020 Early Stage Researcher
  • Fondazione Umberto Veronesi

Zitieren

APA

Gragera, P., Scaldaferri, V., & Fruci, D. (2026). Moonlighting ERAP Aminopeptidases in Cancer: Beyond Antigen Processing. Cells. https://doi.org/10.3390/cells15171609

Vancouver

Gragera P, Scaldaferri V, Fruci D. Moonlighting ERAP Aminopeptidases in Cancer: Beyond Antigen Processing. Cells. 2026. doi:10.3390/cells15171609

BibTeX
@article{Gragera2026,
  author = {Gragera, Paula and Scaldaferri, Valentina and Fruci, Doriana},
  title = {Moonlighting ERAP Aminopeptidases in Cancer: Beyond Antigen Processing},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15171609}
}
Kostenlos starten →